老年人的他汀类药物治疗被引量：3

Application of Statins in the Elderly

下载PDF

导出

摘要随着我国进入老龄化社会,心脑血管疾病已经成为威胁生命的重要疾病,他汀类药物被视为安全有效的调脂药物,已成为各国心脑血管疾病防治指南的推荐用药。本文参考2009年我国老年学学会心脑血管病专业委员会起草的《中国血脂异常老年人使用他汀类药物的专家共识》,结合最新的他汀类药物治疗的相关文献进行分析,希望获得老年他汀类药物治疗的最新认识。 Cardiovascular diseases（CVD） have become a major life-threatening diseases in aging societies.Statins,as effective and safe treatment for lowering lipids,have been recommended for CVD prevention and treatment in many countries.Based on the Expert Concensus on the Application of Statins in Elderly Individuals with Abnormal Blood Lipids,which was developed by Chinse Society of Gerontology CVD Committee in 2009,this articles reviews the up-to-dated literature with an attemtp to reach new understandings on the application of statins in this population.

作者张丽芳

机构地区中日友好医院心内科

出处《中国全科医学》 CAS CSCD 北大核心 2012年第14期1551-1553,共3页 Chinese General Practice

关键词老年人 80以上他汀药物治疗一级预防 Aged 80 and over Statin Pharmacotherapy Primary prevetion

分类号 R972 [医药卫生—药品]

引文网络
相关文献

参考文献18

1Afilalo J, DuqueG, Steele R, et al. Statins for secondary prevention in elderly patients. A hierarchical bayesian meta- analysis [ J ]. J Am Coil Cardiol, 2008, 51 (1): 37-45.
2Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholester- ol levels: results of AFCAPS/TexCAPS [ J]. JAMA, 1998, 279 (20) : 1615 - 1622.
3Sever PS, Dahof B, poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo - Scandinavian Cardiac Outcomes Trial - Lipid Lowering Ann ( ASCOT - LLA) : a multicentre randomised controlled trial [ J ]. Lancet, 2003, 361 (9364) : 1149 -1158.
4Lemaitre RN, Psaty BM, Heckbert SR. et al. Therapy with hydroxym- ethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults [ J ]. Arch Intern Med, 2002, 162 (12): 1395-1400.
5Ridker PM, Danielson E, Fonseea FA, et al. Rosuvastatin to provent vascular events in men and women with elevated C - reactive protein [J]. NEnglJne, 2008, 359 (21): 2195-2207.
6Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol - lowering therapy in women and elderly patients with myocardial infarction or angi- na pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) [J]. Circulation, 1997, 96 (12) : 4211 -4218.
7Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardio- vascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the lipid trial [J]. Ann Intern Med, 2001, 34 (10) : 931 -940.
8Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause - specific mortality and on cancer in- cidence in 20, 536 high - risk people: a randomised placebo - con- trolled trial [J]. BMC Med, 2005, 3: 6.
9Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly indi- viduals at risk of vascular disease (PROSPER): a randomised con- trolled trial [J]. Lancet, 2002, 360 (9346) : 1623 -1630.
10Deedwania P, Stone PH, Merz CN, et al. Effects of intensive versus moderate lipid - lowering therapy on myocardial ischemia in older pa- tients with coronary heart disease. Results of the Study Assessing Goals in the Elderly (SAGE) [J]. Circulation, 2007, 115:700-707.